- Home
- ALVO vs IMVT Comparison
ALVO vs IMVT Comparison
Compare ALVO & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVO
- IMVT
- Stock Information
- Founded
- ALVO 2013
- IMVT N/A
- Country
- ALVO Luxembourg
- IMVT United States
- Employees
- ALVO N/A
- IMVT N/A
- Industry
- ALVO Biotechnology: Pharmaceutical Preparations
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALVO Health Care
- IMVT Health Care
- Exchange
- ALVO Nasdaq
- IMVT Nasdaq
- Market Cap
- ALVO 2.5B
- IMVT 2.5B
- IPO Year
- ALVO N/A
- IMVT N/A
- Fundamental
- Price
- ALVO $9.38
- IMVT $14.30
- Analyst Decision
- ALVO Buy
- IMVT Buy
- Analyst Count
- ALVO 1
- IMVT 10
- Target Price
- ALVO $18.00
- IMVT $40.14
- AVG Volume (30 Days)
- ALVO 140.4K
- IMVT 1.5M
- Earning Date
- ALVO 05-07-2025
- IMVT 05-28-2025
- Dividend Yield
- ALVO N/A
- IMVT N/A
- EPS Growth
- ALVO N/A
- IMVT N/A
- EPS
- ALVO 0.34
- IMVT N/A
- Revenue
- ALVO $587,890,000.00
- IMVT N/A
- Revenue This Year
- ALVO $33.92
- IMVT $108.88
- Revenue Next Year
- ALVO $45.74
- IMVT N/A
- P/E Ratio
- ALVO $27.67
- IMVT N/A
- Revenue Growth
- ALVO 413.92
- IMVT N/A
- 52 Week Low
- ALVO $7.35
- IMVT $12.72
- 52 Week High
- ALVO $14.65
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- ALVO 58.67
- IMVT 41.40
- Support Level
- ALVO $7.90
- IMVT $14.84
- Resistance Level
- ALVO $8.50
- IMVT $16.44
- Average True Range (ATR)
- ALVO 0.39
- IMVT 0.94
- MACD
- ALVO 0.18
- IMVT 0.05
- Stochastic Oscillator
- ALVO 67.72
- IMVT 30.52
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).